METiS TechBio enters a collaboration with Eli Lilly to develop next-generation, tissue-specific lipid nanoparticle delivery technologies using METiS’s AI-driven lipid discovery platform.
Feature|Articles|August 20, 2026
How to Rebuild Pharma Operating Model for an AI Era
In pharma's AI transformation, the technology was never the hard part — fixing the operating model that has to act on what AI surfaces is.
Advertisement
Advertisement
In the early 2000s, AstraZeneca’s gefitinib program in lung cancer was widely viewed as disappointing based on overall trial results. Yet buried within the data was a striking signal: a subgroup of patients experienced dramatic tumor responses—patients later shown to carry EGFR mutations. The finding became a landmark in biomarker-driven oncology, proving that the right therapy can look ineffective in the average patient while being transformative for the right subgroup.
Related to this article
Merck KGaA, Darmstadt, Germany, agrees to acquire Silence Therapeutics for roughly $1.3 billion, gaining a siRNA asset, divesiran.
Roche licenses Rona Therapeutics’ ALK7-targeting RNAi candidate for obesity, while Pfizer partners with Enodia Therapeutics on Sec61 inhibitor discovery.
As CROs, labs, and other outside partners gain early access to trial and FDA data that sponsor employees have, experts say closing the gap starts with rewriting confidentiality language.
PaxSafe's Mark Talens on why pharma supply chain AI fails before it starts — and the data foundry framework that changes that.
Thomas Appio has been named interim CEO of Bausch + Lomb, a move coinciding with an expected upward revision to the company’s full-year guidance.
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Advertisement
Advertisement